drugset / Trial / NCT06134284
Clinical Study of OR for Second-line Treatment of Refractory MZL
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to test the overall response rate of Orelabrutinib combined with rituximab (OR regimen) for second-line treatment of relapsed/refractory marginal zone lymphoma.
Timeline
- Start
- 2023-01-02
- Primary completion
- 2026-12-31
- Completion
- 2029-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | Orelabrutinib | Small molecule | 150 mg | Oral |
| Background | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |